Amvuttra 25 mg solution for injection in pre-filled syringe, Onpattro 2 mg/mL concentrate for solution for infusion. clinical trials

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

This study is testing a new medicine, Amvuttra, for a rare inherited condition called hereditary transthyretin amyloidosis (hATTR amyloidosis). It aims to see if Amvuttra is safe and helps improve symptoms compared to standard treatments.